Growth Through Acquisition BÜHLMANN recently joined forces with KLAR Partners to support growth, signaling a strategic expansion phase. This presents sales opportunities to align with KLAR Partners’ portfolio approach and offer complementary in-vitro diagnostics solutions or integration services for expanded geographic reach.

Global Reach With local teams across Europe, the USA, Brazil, and distributors worldwide, there is a ready-made channel network to introduce new calprotectin and therapeutic drug monitoring solutions. Leverage existing relationships to accelerate market access and cross-sell broader assay portfolios.

Calprotectin Leader BÜHLMANN offers the broadest calprotectin solution set, including automated and high-throughput turbidimetric and ELISA assays. This positions the company to upsell integrated workflow solutions, automation hardware, and service contracts to labs seeking scalable testing capacity.

Quality and Compliance Manufacturing under GMP with EN ISO 13485:2016 and MDSAP certification creates a strong selling point for hospital networks and reference labs prioritizing regulatory-compliant diagnostics. Use this to target procurement groups seeking trusted, globally recognized quality marks.

Innovation Pipeline Recent launches such as fCAL turbo and fPELA turbo, along with MPXV/OPXV RUO assays, indicate an active product development rhythm. Highlight opportunities for early adoption deals, co-marketing with strategic distributors, and clinical validation collaborations to drive early traction in new segments.